Carcinoid syndrome historical perspective: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Carcinoid syndrome was first described by Siegfried Oberndorfer, a German [[pathologist]] in 1907. | Carcinoid syndrome was first described by Siegfried Oberndorfer, a German [[pathologist]] in 1907. Endocrine related properties of carcinoids was described by Gosset and Masson in 1914. | ||
==Historical Perspective== | ==Historical Perspective== | ||
Revision as of 13:11, 29 September 2015
|
Carcinoid syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Carcinoid syndrome historical perspective On the Web |
|
American Roentgen Ray Society Images of Carcinoid syndrome historical perspective |
|
Risk calculators and risk factors for Carcinoid syndrome historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Carcinoid syndrome was first described by Siegfried Oberndorfer, a German pathologist in 1907. Endocrine related properties of carcinoids was described by Gosset and Masson in 1914.
Historical Perspective
Carcinoids were first described in 1907 by Siegfried Oberndorfer, a German pathologist at the University of Munich, who coined the term karzinoide, or "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance microscopically. The recognition of their endocrine-related properties were later described by Gosset and Masson in 1914, and these tumors are now known to arise from the enterochromaffin (EC) and enterochromaffin-like (ECL) cells of the gut.